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Abstract
Keratoconus (KC) is the most common primary corneal ectatic disease which has considerable importance in public
health. Corneal collagen crosslinking (CXL) is a procedure to mitigate progression of KC and reduce demand for
corneal transplantation. Although studies have proven the efficacy of CXL regarding corneal shape, none have
investigated the effects of CXL on tear biomarkers which are useful tools to understand molecular mechanisms
behind CXL. Our purpose was to determine the effect of CXL on tear mediators in patients with KC and analyze
associations with corneal changes. Tear samples were collected pre-CXL from 26 eyes of 23 patients and during a
12-month follow-up. The mediators’ concentration was measured by Cytometric Bead Array technology. Corneal
topography parameters measured by Scheimpflug Camera included: Thinnest-corneal-thickness (ThCT), keratometry
values (K1, K2), Radii-Minimum (Rmin), Keratoconus-Index (KI), Center-KI (CKI), Index-of-Height Asymmetry (IHA)
and Index-of-Surface Variance (ISV). At baseline, KI was correlated negatively with chemokine (C-C motif) ligand 5
(CCL5) (p=0.015) and matrix metalloproteinase (MMP)-13 (p=0.007). At day 4, interleukin (IL)-6 and IL-8 increased,
while IL-13, IL-17A, interferon (IFN)-γ, CCL5, MMP-13, epidermal growth factor (EGF), nerve growth factor (NGF)
and plasminogen activator inhibitor (PAI-1) decreased significantly compared to pre-CXL concentrations (p≤0.02). At
6 months tissue plasminogen activator (t-PA) increased (p=0.02), while at 12 months Rmin increased (p≤0.004), and
IL-6 and CXCL8 (p=0.005 and p=0.047) as well as K1, ISV and KI decreased. After 6 months CKI and ISV showed
significant associations with IL-17A; CKI with IL-13 and ThCT with IL-13 (p≤0.02), while at 12 months there were
reverse associations between ThCT and IL-6, IL-13, INFγ, CCL5 and PAI-1 (p≤0.02). Alterations of mediators in tear
fluid after CXL associate with topographic changes highlight the fact that many mediators are involved in the complex
mechanisms after CXL. Further studies on biomarkers to investigate the efficacy of CXL are needed.
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Introduction
Keratoconus (KC) is a degenerative disorder characterized
by progressive deformation of the corneal architecture
including corneal thinning that gives rise to a cone shaped
cornea [1-3]. Progression of KC is associated with an increase
in the spherical component of the refraction and irregular
astigmatism with consequent deterioration of visual acuity [1,2].
Corneal collagen crosslinking (CXL) is a procedure to
mitigate the progression of KC [3-6]. Many clinical studies have
provided data supporting the efficacy of the treatment:
improvement in corneal shape, including a decrease in corneal
higher-order aberrations, keratometry (K) values and several
quantitative indices of corneal topography [5-10]. The findings
did not always correlate with visual acuity or subjective visual
symptoms [6,8,11].
Generally, KC is believed to be a non-inflammatory disease
with multivariable origin [2]. Some studies have shown that
degradation of stromal collagen is accompanied by expression
of pro-inflammatory cytokines and matrix metalloproteinases
(MMPs) and their inhibitors. Growth factors also play an
important role in the pathogenesis [12-17]. In the tears of
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keratoconic patients increased interleukin (IL)-6, epidermal
growth factor (EGF), MMP-1, -3, -7,-9, -13 and tissue inhibitor
of metalloproteinases-1 (TIMP-1), and decreased interferon
(IFN)-γ, IL-4, IL-5, IL-6, IL-8 (CXCL8), IL-12, IL-13, chemokine
(C-C motif) ligand 5 (CCL5), vascular endothelial growth factor
(VEGF) and alteration of tumor necrosis factor (TNF)-α and
nerve growth factor (NGF) have been described as possible
players in the disrupted corneal homeostasis [14-20]. The
mediators determining the progression or stabilization of KC
have not been well characterized and the effect of CXL on
these factors is in its early state [16,17]. Although corneal
biomechanical and architectural improvements after CXL have
been well documented in the literature, to date, the changes in
the tear film components have been yet explored. It is
important to analyze whether these biomarkers may constitute
determinant factors for the effectiveness of CXL.
In this study, to further asses the pathomechanism of KC
after CXL, we evaluated the short and the long-term effect of
CXL on the concentration of mediators (IL-6, -13, -17A, IFNγ,
CXCL8, CCL5, MMP-9, -13, TIMP-1, tissue plasminogen
activator (t-PA), plasminogen activator inhibitor (PAI-1), EGF
and NGF in tears of patients with KC. In addition, the changes
in concentration of mediators were correlated with the changes
in outcomes: K values, Thinnest corneal thickness (ThCT),
Radii Minimum (Rmin), Keratoconus-Index (KI), Center
Keratoconus Index (CKI), Index of Height Asymmetry (IHA) and
Index of Surface Variance (ISV)) measured by Pentacam over
12 months.
Patients and Methods
Twenty-six eyes of 23 patients (mean age: 28.2 years,
range: 16-60 years, standard deviation (SD): 10) with
progressive KC were enrolled and treated in this prospective
study. All eyes underwent comprehensive ophthalmological
examination and tear sample collection before and after CXL
during the 1-year follow-up period at regular intervals:
preoperatively and at day 4, day 10 visits, and 1, 3, 6 and 12
months after CXL. Twelve eyes of 12 healthy controls (mean
age: 27.8 years, range: 16-67 years, standard deviation (SD):
15.3) were also enrolled in this study.
Following the tenets of the Declaration of Helsinki, written
informed consent was signed by all participants and/or their
parent/guardian prior to enrollment. This study was approved
by the Institutional Ethics Committee of the University of
Debrecen. The inclusion criteria included 16 years of age or
older and axial topography consistent with KC. Rabinowitz
criteria were used for diagnosing KC [21]. Progressive KC was
defined as 1 or more of the following changes over 24 months:
an increase of 1.0 diopter (D) or more in the steepest K value,
an increase of 1.0 D or more in manifest cylinder, or an
increase of 0.5 D or more in manifest refraction spherical
equivalent [6,11]. Exclusion criteria were: previous ocular
surgery, abnormality in lens or retina on biomicroscopic
examination, chemical injury or delayed epithelial healing,
corneal pachymetry less than 300 μm, and pregnancy or
lactation during the course of the study.
Crosslinking Treatment
CXL was performed using InPro CCL-Lix device
(Norderstadt, Germany). Topical anesthesia was administered
and the corneal epithelium removed by mechanical
debridement over the central 8.0 mm. A 0.1% riboflavin
solution (with 20% dextran) was then administered topically
every 2 minutes for 30 minutes. After riboflavin administration,
its absorption throughout the corneal stroma and anterior
chamber was confirmed by a slitlamp examination. Pachymetry
(obtained with Pentacam) was performed and if the cornea was
less than 400 μm (4 out of 26 eyes), hypotonic riboflavin (0.1%
in sterile water; Medio Cross sine, Medio-Haus
Medizinprodukte GmbH) was administered, 1 drop every 10
seconds for 2 minute sessions, after which pachymetry was
performed to confirm that the stroma had swollen to 400 μm or
more [11,22]. This was repeated until adequate corneal
thickness was obtained. The cornea was exposed to ultraviolet-
A (UV-A) 365 nm light for 30 minutes at an irradiance of 3
mW/cm2. The postoperative treatment was antibiotic eye drops
for 7 days (tobramycin), steroid eye drops (fluorometholone)
and artificial tear drops for at least 3 months. No contact lenses
were used postoperatively.
Measurements
All eyes had a complete ophthalmological evaluation,
including keratometry, best-corrected visual acuity
measurements, slit-lamp biomicroscopy (under low illumination
to avoid reflex tearing), and Rotating Scheimpflug topography
(Pentacam HR, Oculus Optikgeräte GmbH, Wetzlar, Germany)
before CXL and during the 1-year follow-up, at each
opthalmological visit. The following data were exported to
Microsoft Excel (Microsoft Corp, Redmond, Washington):
Holladay equivalent keratometry values in the flat (K1) and
steep (K2) meridian, ThCT, Rmin, KI, CKI, IHA, ISV. For height
data measurements, the toric ellipsoid reference surface was
used [10]. The stage of KC was graded as mild when the
steepest keratometric reading (K2) was <45 diopters (D),
moderate if K2 was between 45 and 52 D, and severe if K2 >52
D. K2 has been considered to be a reliable quantitative clinical
variable to assess the severity of KC [13,16].
Tear collection and analysis
Non-stimulated tear samples were collected from all 26 eyes
of 23 keratoconic patients before CXL and during the 1-year
follow-up at each opthalmological visit and once from the 12
control eyes. The tear collection was carried out with capillary
tubes from the inferior meniscus, without topical anesthesia for
2 min and the total volume of the collected tears registered
[23]. The samples were immediately transferred to Eppendorf
tubes and frozen at -80 °C without centrifugation within 15 min
from collection. Usually, 4 µl tear samples or more could be
collected. In keratoconic patients, the concentrations of IL-6,
CXCL8 (IL-8), CCL5 (RANTES), MMP-9, MMP-13, TIMP-1,
NGF, tPA and PAI were measured in all 157 tear samples,
while the volume of 105 tear samples allowed a second
measurement for IL-13, IL-17A, INFγ and EGF by the
Cytometric Bead Array method. Combined FlowCytomix™
Simplex Kits were used with the appropriate FlowCytomix
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Basic Kit with minor modifications of the manufacturer’s
instructions (eBioscience, Bender MedSystems GmbH, Vienna,
Austria). Briefly, 12.5 µl of tear samples (if needed, diluted
samples) or serial dilutions of mixed standard cytokines were
added to 12.5 µl suspension of fluorescent cytokine capture
beads in multiwell filter microplates. 12.5 µl of biotin conjugated
anti-cytokine antibody was added to the wells, then the plates
were incubated for 2 hours on a microplate shaker. The wells
were emptied and washed with a vacuum filtration manifold.
Phycoerythrin conjugated streptavidin was added to the wells
followed by additional incubation for 1 hour and washing. 150
µl assay buffer was applied to the wells, then multiparametric
data acquisition was performed on a FACS Array cytometer
(BD Biosciences Immunocytometry Systems, San Jose, CA).
Data were analyzed with the FlowCytomix Pro 2.3 software.
Additional serial dilutions of the standard were applied to obtain
better sensitivity and therefore, modified standard curves were
generated in the analysis. The detection limits were the
following: IL-6 (1.2 pg/ml), IL-13 (4.5 pg/ml), IL-17A (2.5 pg/ml),
INFγ (1.6 pg/ml), CXCL8 (0.5 pg/ml), CCL5 (25 pg/ml), MMP-9
(95 pg/ml), MMP-13 (50 pg/ml), TIMP-1 (28 pg/ml), NGF (126.8
pg/ml), EGF (22.7 pg/ml), tPA (4.8 pg/ml) and PAI-1 (13.5 pg/
ml).
Statistical methods
Variables were described in terms of means and SD on their
native scales. For all analytical procedures, keratometric
variables and mediators in the tear samples were transformed
to improve normality using zero-skewness log transformation.
Paired 2-tailed Student’s t tests were used to analyze post-
CXL changes from baseline for all 13 mediators and the 8
variables obtained from Pentacam.
Multilevel mixed-effects linear regression was used to
analyze the association between the concentration of the 13
mediators and keratometric readings obtained from
Scheimpflug Camera (ThCT, K1, K2, Rmin, KI, CKI, IHA, ISV).
Models were fitted separately for each possible pairing
between mediators and keratometric variables, with adjustment
for contact lens wear and tear volume, and interaction terms
between measurement occasion and mediator concentration.
The statistical package applied was Stata version 11. The
significance criterion was set at α=0.05.
Results
Twenty-six eyes of 23 keratoconic patients were enrolled and
underwent CXL in this study (mean age: 28.2+10 years). The
KC was classified as follows: grade 1, 2 eyes (8%); grade 2, 12
eyes (46%); grade 3, 12 eyes (46%). The mean follow-up was
11 months (157-494 days), 18 eyes were followed up to one
year post-CXL.
Short-term non-transformed data were collected up to 38
days from CXL (Figure 1). As expected, the collected tear
volume (p<0.0001) and the thinnest corneal thickness
(p=0.0005) increased significantly 4 days after the treatment.
Despite the excessive tearing at day 4, there were statistically
significant increases in the concentrations of IL-6 and CXCL8
(p<0.0001) when compared to the pre-operative (pre-CXL)
baseline levels. At the same time, the concentration of IL-13
(p=0.01), IL-17A (p=0.001), IFNγ (p=0.02), CCL5 (p=0.001),
MMP-13 (p=0.02), EGF (p<0.0001), NGF (p=0.01) and PAI-1
(p=0.001) decreased significantly, and there were no significant
changes in the concentrations of MMP-9, TIMP-1 and t-PA.
The changes in the concentration of all the mediators 38 days
after CXL compared with the baseline failed to reach statistical
significance, and the volume of the collected tears returned
back to the pre-CXL levels. The thinnest corneal thickness
were significantly decreased (p<0.0001) after CXL compared to
the baseline data at day 38.
The pre-CXL and post-operative long-term data in patients
with keratoconus and the data from the healthy controls,
including the Pentacam results and the concentration of the
mediators without any adjustment are shown in Table 1
(significant differences at 6 and 12 months compared to the
baseline data with adjustment are indicated). At 6 months,
there was a significant decrease in ThCT and ISV (p=0.03 and
p=0.0005) and increase in Rmin (p=0.007). At 12 months, the
change in K1, ISV and KI were statistically decreased
compared to the baseline (p=0.0045, p=0.002, p=0.0005;
respectively), while Rmin was increased (p=0.0004). At 6
months, there was a significant increase in tPA (p=0.023),
while at 12 months, there was a significant decrease in IL-6
and CXCL8 (p=0.005 and p=0.047). The changes in other
enzymes and growth factors compared to the baseline failed to
reach statistical significance at 6 months or 12 months.
However, when the pre-CXL levels of the mediators were
divided into low or high subgroups and were analized
individually, many significant changes were observed at the
two observed time points. In the low concentration pre-CXL
subgroup, a significant elevation in IL-6 (p=0.016), IL-13
(p=0.001), IL-17A (p=0.004), IFNγ (p=0.013), CCL5 (p=0.013),
MMP-9 (p=0.01), MMP-13 (p=0.0003), TIMP-1(p=0.011), NGF
(p=0.04), tPA (p=0.007) and PAI-1 (p=0.017) was observed at
6 months, while only the IL-13 (p=0.009) and MMP-13
(p=0.024) were elevated at 12 months. In the high
concentration pre-CXL subgroup, significant decreases were
observed after 6 months in IL-13 (p=0.007) and IL-17A
(p=0.001), while at 12 months the IL-6 (p=0.0002), IL-13
(p=0.049), IL-17A (p=0.019), CXCL8 (p=0.003), CCL5
(p=0.0012), MMP-9 (p=0.025), MMP-13 (p=0.047), NGF
(p=0.014), EGF (p=0.013) and PAI-1 (p=0.007) showed the
same decreasing trend as IL-13 and IL-17A after 6 months.
The concentration of all the examined mediators in the tear
samples from the control eyes were significantly lower when
compared to the pre-operative (pre-CXL) baseline levels in
patients (p<0.05).
At baseline, KI was correlated negatively with CCL5
(p=0.015) and MMP-13 (p=0.007). We then examined the
linear association between the different mediators and the
tomography data. After 3 months, KI was associated negatively
with IL-17A (p=0.002) and MMP-13 (p=0.01); similarly IHA was
negatively associated with IL-17A (p=0.016) and EGF
(p=0.032). After 6 months, CKI and ISV showed significant
associations with IL-17A (p=0.001 and p=0.016, respectively),
similar to CKI with IL-13 (p=0.002) and ThCT with IL-13
(p=0.01). After 12 months, there were reverse associations
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between the thinnest corneal thickness (ThCT, Pachy Min) and
IL-6 (p=0.005), IL-13 (p= 0.017), IL-17A (p=0.049), INFγ
(p=0.017), CCL5 (p=0.02) and PAI-1 (p=0.011).
Discussion
To the best of our knowledge, there are no studies
evaluating the effect of the corneal cross-linking procedure on
different tear biomarkers. Our results show significant changes
in the level of several proteins including cytokines, chemokines,
Figure 1.  Short-term changes in the concentration of mediators in the tear fluid after corneal collagen crosslinking.  a. the
concentration of interleukin(IL)-6 and IL-8 (CXCL8) increased 4 days after CXL; b. matrix metalloproteinase(MMP)-9, plasminogen
activator inhibitor (PAI)-1, IL-17A and IFN-gamma showed no changes 38 days after CXL compared to the baseline; c. tissue
plasminogen activator (tPA), RANTES (CCL5), MMP-13 and nerve growth factor (NGF) increased slightly 38 days after CXL
compared to the baseline; d. tissue inhibitor of metalloproteinases (TIMP)-1, IL-13 and epidermal growth factor (EGF) decreased
slightly 38 days after CXL compared to baseline; e-f. Short-term changes in the collected tear volume and the thinnest corneal
thickness (Pachy min.).
doi: 10.1371/journal.pone.0076333.g001
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enzymes (and inhibitors) and grow factors in tear samples after
CXL with concomitant changes in the shape of KC corneas.
Although this morphological regression effect of CXL has
already been reported by several previous studies
[3,5-11,24,25], this is the first high-throughput study to
demonstrate the effect of CXL on tear mediators. In this study,
the postoperative changes in 8 Pentacam topography indices
were evaluated and the associations between the different
protein concentrations were followed up to 12 months providing
a more comprehensive analysis of the potential effect of CXL
on keratoconic corneas. The only study investigating the
expression of mediators after CXL has involved patients 3 to 6
months postoperatively, and tears were collected during single
study visits without comparing the data with the pre-CXL
baseline-levels [17]. Our study collected tear samples from
patients with progressive KC and at regular intervals during 1
year after CXL. Cytokines, chemokines, enzymes, and growth
factors are important in wound healing and tissue redistribution
response of corneal tissue, regulating the wound healing,
apoptosis, cell cycling and migration processes under
physiological or pathological conditions. It is assumed that
biomarkers examined in our study and others from this
complex network may be responsible for clinical outcomes after
CXL treatment.
Previous studies of patients with progressive KC after CXL
found significant improvement in several Pentacam topography
indices (CKI, KI, IHA, Rmin, ISV and IVA) [5-10,24]. The
improvements of K1, KI, ISV, ThCT and Rmin detected in our
study are consistent with these previous findings supporting the
fact that the cornea is assuming a more regular shape after
CXL. Our results are in line with the previous findings that
collagen CXL is an effective procedure.
The CXL treatment of de-epithelialized corneas causes a
prompt, excessive release of several mediators independent of
the long-term effect of the procedure, and due to the
mechanical (epithelial removal), chemical (riboflavin soaking)
and physical (UVA irradiation) stress on the cornea. Since the
volume of the collected tear volumes during 2 mins can differ
significantly in the post-CXL period at 1 month compared to the
pre-CXL volumes, and due to the diluting effect from excessive
tearing on the ocular surface, the estimates of the mediator
concentrations on keratometric readings were adjusted for the
collected tear volume. Besides the presence of excessive
tearing under certain conditions, the concentration of IL-6 and
CXCL8 significantly increased in our study 4 days after CXL
(p<0.0001), suggesting the prompt involvement of inflammatory
cells in the process. By day 4, the ThCT increased significantly
(p=0.0005) and this swelling dramatically decreased at day 38
(p<0.0001). This edematous process in the corneal stroma in
the early post-CXL phases has been already described before
[26]. The concentration of several mediators decreased
significantly because of the diluting effect of the tearing. The
CXL treatment retards the progression of KC by cross-linking of
collagen molecules. Although the complex pathophysiology of
CXL is unclear, the early clinical worsening and the transitional
alteration of the mediators coincide with the epithelial
debridement, re-epithelization process and post-operative
keratocyte apoptosis and repopulation as well as new collagen
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synthesis [8,26,27]. UVA causes the keratocytes in the outer
layers of the treated part of the cornea to undergo cell death
[7]. By definition, in order to crosslink tissue, keratocytes must
be killed. When cells die through necrosis, a strong
inflammatory response is initiated and a release of various
mediators including chemokines occurs. IL-1 is the master
regulator of sterile inflammation and is derived from necrotic
corneal epithelial cells which can induce the production of IL-6,
stimulating the migration of corneal epithelial cells [28].
Necrotic corneal epithelial cells enhance the production and the
release of CXCL8, and with its chemotactic activity CXCL8 can
influence the inflammatory cells. In the early-phase after CXL,
the extremely elevated release of IL-6 and CXCL8, detected in
our study, contribute significantly to the corneal epithelial
wound healing process and the recruitment of inflammatory
cells into the corneal stroma, resulting in prevention of tissue
damage from excessive inflammation by clearance of damaged
cells [28]. After CXL, all corneal layers regenerate rapidly, even
the epithelial regrowth is complete after four days [27]. After re-
epithelisation of the cornea, remodelling and reorganization
occur, new keratocytes migrate into the central area over
several months following CXL. In the early stages of the
recovery from CXL and at 38 days after CXL, the changes in
the concentration of all the mediators and even the volume of
the collected tears during 2-min return back to the pre-CXL
levels. Gradual repopulation of the corneal stroma, starting
between the second and third month after the intervention, is
usually completed within six months [27].
KC is definied as a non-inflammatory disease of the cornea,
but increasing number of studies show an over-expression of
several cytokines in it [16,17], therefore, classifying the disease
as non-inflammatory may be inappropriate [29]. The decrease
in the concentration of IL-6 (p=0.005) 12 months after CXL
shown in the current study supports the previous reported
observation that IL-6 is the only cytokine which significantly
differed in the tears of KC subjects compared to the CXL group
[17]. In addition, we have shown a strong negative correlation
between IL-6 and ThCT 1 year after CXL. We could detect
significant decrease of CXCL8 at that time point, which also
supports the assumption that cytokines and chemokines play
an important role in the pathomechanism of KC and that CXL
treatment may be able to alter the inflammatory response.
CXCL8 is a potent chemotactic factor in the human tears. A
decreasing trend towards the TH1 cytokines (IFNγ) in KC, may
suggest presence of complex imbalance in the cytokines
leading to altered epithelial and stromal function in this disease
[16]. The decrease in the levels of IL-6 and CXCL8 after CXL
treatment could be considered as positive for corneal health
because the levels of these cytokines of healthy controls in our
study were significantly lower compared to the patients. This
might be a contributing factor in the stabilization of this corneal
disease. The analysis of the long-term associations after CXL
have revealed reverse association between ThCT and IFNγ.
Jun et al. observed decreased IL-13 level in tears of severe KC
and an increasing trend in IL-17 [16]. IL-13 plays crucial roles
in amplification of the TH2 response, and the decreased levels
suggest that TH2 responses may be dampened in KC [16].
Dermal fibroblasts stimulated with IL-13 upregulate the
production of collagens type I and III [30]. IL-17 is produced
primarily by the TH17 subset T lymphocytes, and it can also
mediate induction of fibroblasts as well as production of tissue
degrading proteases and cytokines [31]. IL-13 and IL-17 in our
study showed significant long-term (6 and 12 months)
associations with topography indices (ISV, CKI, ThCT).
Additional studies are needed to further validate the role of
IL-13 and IL-17 in tissue damage and the effect of CXL in KC.
Our baseline findings that KI correlates negatively with CCL5 is
in line with Jun et al. - the only group having reported tear
sample measurements of CCL5 and reporting lower levels in
KC [16]. Our baseline observation and a reversely significant
association between ThCT and CCL5, 1 year after CXL
underline the importance of CCL5 in the pathomechanism of
KC.
MMPs are secreted in response to cytokines and growth
factors and elevated levels of MMPs in the tear fluid of KC
patients indicates a tissue degenerative process contributing to
the thinning of the cornea [14,17,19]. MMPs and cytokines
interact with each other forming a complex network, including
the stimulation of MMP-9 and MMP-13 by IL-6 [17]. The active
form of t-PA converts plasminogen to plasmin, which can also
degrade several components of the extracellular matrix and
trigger activation of the MMP pathway. MMPs and PAs in turn
are partially regulated by TIMPs and PAIs, inhibiting this
cascade system and therefore influencing KC progression. The
PAI-1 gene can be induced by several growth factors and
cytokines, and it can inhibit the activity of t-PA enzymes. A
significant increase in tPA was detected in our study 6 months
after the CXL treatment and after 1 year, a reverse association
was observed between ThCT and PAI-1. MMPs participate in
extracellular matrix remodelling following CXL, and a positive
correlation between keratometry and MMP-13 and TIMP-1
levels in the tear film in KC has been observed by others
without any information on the pachometric data [17]. In our
study, a negative correlation could be observed between
concentrations of MMP-13 and KI at baseline and 3 months
post-CXL. TIMPs are natural inhibitors of the different MMPs,
and there have been various studies with conflicting reports on
the expression of TIMP-1 in KC corneas [15,17,32,33]. In our
study, we could not detect any correlation or alteration in the
levels of MMP-9 and TIMP-1, which suggests, that other
MMPs, as well as other enzymes might play a more crucial role
in the underlying molecular mechanism following CXL, and
probably, the actual enzyme activities influence the final effect.
TIMP-1 has been observed to prevent TIMP-3 induced
apoptosis of keratocytes [33], therefore the lack of the
alteration of TIMP-1 concentration after CXL may be beneficial
to KC patients. Since protease activity has not been analized in
this study and it may have importance in the pathogenesis of
KC (significantly elevated activity of collagenases have been
found, while reduced protease activities have been observed
after CXL) [17,34,35], future studies may need to confirm the
active interplay between MMPs and ILs.
Early post-operative in vivo confocal microscopic analysis
has shown an immediate disappearance of the subepithelial
plexus and the anterior-midstromal nerve fibers [25]. The nerve
regeneration after CXL is very rapid, and is almost complete six
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months after the treatment [27]. The ocular surface healing,
including corneal epithelial cell proliferation and immune-
modulating actions of NGF have been extensively studied [36].
In our study, during the early postoperative period, when the
re-epithelization process is dominant, a slightly increase in
NGF could be observed, but no association or long-term
changes in the concentration of NGF could be detected after
CXL. The role of NGF in the pathogenesis of KC is under
investigation and because its role in the proliferation of limbal
epithelial progenitor cells is suggested [36], further studies are
required to demonstrate the importance of NGF after CXL
treatment. EGF is produced by lacrimal glands and plays a role
in cell proliferation, migration and apoptosis as well, and has
been found to be up-regulated after epithelial injury [37].
It is important to mention here that the use of steroid eye
drops and their duration after CXL highly depend on the
ophthalmologists’ practice. In generally, steroids are
administered 0-4 weeks after CXL treatment [5-8,11,22,27]. In
contrast, we have used fluorometholone drops for minimum 3
months and found no increase in the mean intraocular pressure
postoperatively (data not shown). Corneal thickness and
posterior elevation at minimum pachymetry proved to be highly
reliable diagnostic parameters of KC and to monitor the
treatment efficacy after CXL [10]. Currently, the long-term
effects of CXL treatment are not well known [4,7], but based on
our findings, the steroid treatment may also influence the post-
CXL changes. The causes of the increase in central corneal
thickness after the second year described by Raiskup-Wolf et
al. and our findings that ThCT did not decrease 1 year after
CXL should be studied further [4]. The standardized, applied
CXL protocol supposes approximately equal penetration depth
in all eyes - the CXL may affect the deeper stromal tissues of
thinner corneas compared to less advanced cases with thicker
corneas [10]. Since steroids have been shown to inhibit
collagen synthesis, prevent collagen accumulation and
decrease collagen turnover in animal models, steroid therapy
has been recommended to be prolonged over a month only in
case of risk of corneal opacity after CXL [27].
To better ascertain differences in response to CXL, low and
high baseline levels of mediators subgroups were compared
here. Many significant long-term changes have been observed
in our study and the different trends may indicate the different
effects mediators in the tear film may have, playing important
role in the cornea homeostasis.
A limitation of this study is that it cannot exclude the
possibility of other mediators being involved in the post-CXL
period and the identification of the source and activity of the
mediators and the expression of the different receptors.
Furthermore, we could compare the pre- and the post-CXL
findings with the baseline data of the patients and also with a
healthy control group, but ideally, because of possible
progression of the disease that can be accompanied with
alteration in the mediator levels, the same number of fellow
eyes with the same severity of KC without any treatment would
have been desired to be the control group, but when
progression is detected, treatment is usually indicated and the
long term results would be limited to reach. Although it has
been demonstrated that mediators are associated with the
severity of KC, it is unclear which proteins can be used to
distinguish non-progressive form of KC from progressive,
where the early CXL treatment would be very important. It
would be of great benefit to understand which biomarkers may
promote the effect of CXL treatment. Tear samples are an
essential tool to understand the molecular mechanism behind
CXL and the multiplex platform is ideally suited for the
detection of biomarkers from tear samples. Several other types
of mediators would be interesting to measure, but without
pooling the tear samples, the number of the proteins that can
be measured is limited. Despite these limitations, it is important
to emphasize that our results highlight the fact that many
mediators are involved in the complex mechanisms after CXL.
It remains to be determined in further studies which of these
mediators or any others are critical in the etiopathogenesis of
the disease and have significance after CXL.
In summary, this study reveals many mediators being altered
in the tears of KC patients after CXL, and these alterations may
have an impact on the effect of this treatment. As a next step,
the precise role of these mediators needs to be defined and it
is important to confirm the observed changes in a larger study
to gain further insight into the molecular alterations after
corneal CXL treatment. This might then serve as a platform for
local inhibition of pathologic corneal thinning or individualized
treatment. Further studies determining the pre-operative
predictors of patients in whom outcomes significantly improve
or worsen after CXL treatment are also needed. Additionally,
studies are required to further elucidate the effect of the
change of mediators after CXL with the different stages of KC.
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